Abeona Cash from 2010 to 2026
| ABEO Stock | USD 5.01 0.02 0.40% |
Cash | First Reported 1996-03-31 | Previous Quarter 163.5 M | Current Value 83.2 M | Quarterly Volatility 28.9 M |
Check Abeona Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abeona Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 5.1 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 33.43, Dividend Yield of 6.5 K or PTB Ratio of 5.8. Abeona financial statements analysis is a perfect complement when working with Abeona Therapeutics Valuation or Volatility modules.
Abeona | Cash | Build AI portfolio with Abeona Stock |
Evaluating Abeona Therapeutics's Cash across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Abeona Therapeutics's fundamental strength.
Latest Abeona Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Abeona Therapeutics over the last few years. Cash refers to the most liquid asset of Abeona Therapeutics, which is listed under current asset account on Abeona Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Abeona Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Abeona Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Abeona Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abeona Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Abeona Cash Regression Statistics
| Arithmetic Mean | 32,736,631 | |
| Geometric Mean | 13,036,614 | |
| Coefficient Of Variation | 127.07 | |
| Mean Deviation | 28,887,394 | |
| Median | 18,750,000 | |
| Standard Deviation | 41,598,113 | |
| Sample Variance | 1730.4T | |
| Range | 137.4M | |
| R-Value | 0.12 | |
| Mean Square Error | 1820.4T | |
| R-Squared | 0.01 | |
| Significance | 0.65 | |
| Slope | 966,069 | |
| Total Sum of Squares | 27686.4T |
Abeona Cash History
Other Fundumenentals of Abeona Therapeutics
Abeona Therapeutics Cash component correlations
Click cells to compare fundamentals
About Abeona Therapeutics Financial Statements
Abeona Therapeutics investors utilize fundamental indicators, such as Cash, to predict how Abeona Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Pair Trading with Abeona Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Abeona Stock
| 0.61 | ABNX | Abionyx Pharma SA | PairCorr |
| 0.55 | OSE | OSE Pharma SA | PairCorr |
| 0.44 | OB3 | OPTIBIOTIX HLTH PLC | PairCorr |
| 0.44 | RAC | Race Oncology | PairCorr |
| 0.43 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Abeona Therapeutics Correlation against competitors. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Abeona diversify its offerings? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Abeona Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 1.21 | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Investors evaluate Abeona Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Abeona Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Abeona Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Abeona Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abeona Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Abeona Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.